Loading...
Loading...
Browse all stories on DeepNewz
VisitWill the study results be published in a top-tier oncology journal by December 31, 2024?
Yes • 50%
No • 50%
Publication records from journals like The Lancet Oncology, JAMA Oncology, or NEJM
Immutep Reports Positive Results in PD-L1-Negative Head and Neck Cancer with Eftilagimod Alpha and Pembrolizumab
Jul 12, 2024, 01:54 PM
Immutep has reported positive results in first-line treatment of head and neck squamous cell carcinoma (HNSCC) patients with negative PD-L1 expression. The results were achieved using a combination of Eftilagimod Alpha and Pembrolizumab, which generated a favorable overall response rate (ORR). This announcement has led to an 18.4% pre-market increase in Immutep's stock price ($IMMP). The findings were highlighted during the ESMO Virtual Plenary and have been met with significant interest in the oncology community. The results were reported by SI.
View original story
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
3 - 4 • 25%
0 • 25%
5 or more • 25%
1 - 2 • 25%
Above 30% • 25%
20% - 30% • 25%
Below 10% • 25%
10% - 20% • 25%